Phase I Study of the mTOR Inhibitor Ridaforolimus and the HDAC Inhibitor Vorinostat in Advanced Renal Cell Carcinoma and Other Solid Tumors

Investigational New Drugs - Netherlands
doi 10.1007/s10637-015-0261-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase I Study of the Pan-Pi3k Inhibitor Buparlisib in Adult Chinese Patients With Advanced Solid Tumors

Anticancer Research
MedicineCancer ResearchOncology
2016English

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2006English

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2019English

A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

Oncotarget
Oncology
2016English

A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

Synergistic Activity of the mTOR Inhibitor Ridaforolimus and the Antiandrogen Bicalutamide in Prostate Cancer Models

International Journal of Oncology
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy